Patricia Balsas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patricia Balsas has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- José Manuel García-Aznar
Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain
2 shared publications - Julián Pardo
Department of Microbiology, Pediatry, Radiology and Public Health, University of Zaragoza, Zaragoza, Spain
2 shared publications - Pilar Alamán-Díez
Multiscale in Mechanical & Biological Engineering Research Group Aragon Institute of Engineering Research (I3A) School of Engineering & Architecture University of Zaragoza Zaragoza Aragon Spain
2 shared publications - Alejandra González-Loyola
Ludwig Institute for Cancer Research Lausanne, University of Lausanne 1 Department of Fundamental Oncology Epalinges
1 shared publication Alejandro Martín-Contreras
Multiscale in Mechanical & Biological Engineering Research Group, Aragón Institute of Engineering Research (I3A), School of Engineering and Architecture, University of Zaragoza, Zaragoza, Spain
1 shared publication- Alvaro Eguileor
Department of Medicine, University of California San Diego, La Jolla, California, USA
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Cell Death & Disease
Targeting hypersialylation in pancreatic cancer microfluidic models reverses its malignant phenotype and enhances CAR-T therapy
Pancreatic ductal adenocarcinoma (PDA) exhibits extensive hypersialylation, a glycosylation hallmark associated with tumor progression and immune evasion. Here, we employed physiologically relevant 3D microfluidic models, which mimic key aspects of the tumor microenvironment, to evaluate the impact of sialyltransferase inhibition using the sialic acid analog Ac 5 3F ax Neu5Ac in PDA cell models. This glycomimetic compound reduced α2,3-sialylation without compromising cell viability in self-organized PDA spheroids. Desialylation decreased the number and velocity of migrating cells in confined and unconfined microenvironments, and reduced cell adhesion to engineered endothelial vessels, consistent with reduced metastatic ability. Notably, 3D co-culture with CAR-T cells revealed enhanced T cell-mediated cytotoxicity upon sialylation inhibition, leading to reduced spheroid size and viability. Collectively, this work provides new insights into the role of sialylation in modulating tumor morphology, cell viability, migratory behavior, and interactions with immune effector cells, underscoring the value of biomimetic microfluidic models for evaluation of anti-metastatic strategies. Overall, targeting hypersialylation reprograms the malignant phenotype of PDA and may enhance immunotherapeutic efficacy, supporting the development of glycan-targeting strategies in cancer therapy.
- 2 November 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessTargeting hypersialylation in pancreatic cancer microfluidic models reverses its malignant phenotype and enhances CAR-T therapy
Pancreatic ductal adenocarcinoma (PDA) exhibits extensive hypersialylation, a glycosylation hallmark associated with tumor progression and immune evasion. Here, we employed physiologically relevant 3D microfluidic models, which mimic key aspects of the tumor microenvironment, to evaluate the impact of sialyltransferase inhibition using the sialic acid analog Ac 5 3F ax Neu5Ac in PDA cell models. This glycomimetic compound reduced α2,3-sialylation without compromising cell viability in self-organized PDA spheroids. Desialylation decreased the number and velocity of migrating cells in confined and unconfined microenvironments, and reduced cell adhesion to engineered endothelial vessels, consistent with reduced metastatic ability. Notably, 3D co-culture with CAR-T cells revealed enhanced T cell-mediated cytotoxicity upon sialylation inhibition, leading to reduced spheroid size and viability. Collectively, this work provides new insights into the role of sialylation in modulating tumor morphology, cell viability, migratory behavior, and interactions with immune effector cells, underscoring the value of biomimetic microfluidic models for evaluation of anti-metastatic strategies. Overall, targeting hypersialylation reprograms the malignant phenotype of PDA and may enhance immunotherapeutic efficacy, supporting the development of glycan-targeting strategies in cancer therapy.
- Top Cited PapersOpen Access
- 20 February 2026
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 232, 115836
Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing
- 20 February 2026
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 232, 115836
Top Cited PapersOpen AccessMatrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing
- Open Access
- 28 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 213, 426-438
Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors
- 28 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 213, 426-438
Open AccessElevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors
- Open Access
- 27 July 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (4) , 501-513
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma
SOX11 overexpression in Mantle Cell Lymphoma (MCL) has been associated with more aggresive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly known. Here, we demonstrate that SOX11 binds to regulatory regions of two important genes for microenvironment-signals in cancer, (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase (FAK)). Moreover, SOX11-positive xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared to their SOX11-negative counterparts. We show that SOX11 directly up-regulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11-positive MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells and cell proliferation; and display an increased resistance to conventional drug therapies, compared to SOX11-negative MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK- and PI3K-inhibitors reduce SOX11-enhanced MCL cell migration and stromal-interactions, and revert cell adhesion mediated-drug resistance (CAM-DR), to the same levels as SOX11-negative MCL cells. In intravenous MCL xenograft models, SOX11-positive MCL cells display higher cell migration, invasion and growth compared to SOX11-knockdown cells, and specific FAK- and CXCR4-inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion, and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemo-refractoriness in aggressive MCL. Key points SOX11 regulates MCL homing and invasion via direct regulation of CXCR4 and FAK expression, and PI3K/AKT and ERK1/2 signaling activation. SOX11 expression increases cell adhesion mediated-drug resistance (CAM-DR) contributing to a more aggressive MCL phenotype.
- 27 July 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (4) , 501-513
Open AccessSOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma
SOX11 overexpression in Mantle Cell Lymphoma (MCL) has been associated with more aggresive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly known. Here, we demonstrate that SOX11 binds to regulatory regions of two important genes for microenvironment-signals in cancer, (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase (FAK)). Moreover, SOX11-positive xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared to their SOX11-negative counterparts. We show that SOX11 directly up-regulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11-positive MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells and cell proliferation; and display an increased resistance to conventional drug therapies, compared to SOX11-negative MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK- and PI3K-inhibitors reduce SOX11-enhanced MCL cell migration and stromal-interactions, and revert cell adhesion mediated-drug resistance (CAM-DR), to the same levels as SOX11-negative MCL cells. In intravenous MCL xenograft models, SOX11-positive MCL cells display higher cell migration, invasion and growth compared to SOX11-knockdown cells, and specific FAK- and CXCR4-inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion, and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemo-refractoriness in aggressive MCL. Key points SOX11 regulates MCL homing and invasion via direct regulation of CXCR4 and FAK expression, and PI3K/AKT and ERK1/2 signaling activation. SOX11 expression increases cell adhesion mediated-drug resistance (CAM-DR) contributing to a more aggressive MCL phenotype.